|
Gene: RPL7A |
Gene summary for RPL7A |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL7A | Gene ID | 6130 |
Gene name | ribosomal protein L7a | |
Gene Alias | L7A | |
Cytomap | 9q34.2 | |
Gene Type | protein-coding | GO ID | GO:0000470 | UniProtAcc | P62424 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6130 | RPL7A | GSM4909280 | Human | Breast | Precancer | 3.54e-02 | -3.93e-01 | 0.0305 |
6130 | RPL7A | GSM4909281 | Human | Breast | IDC | 1.21e-48 | -3.75e-01 | 0.21 |
6130 | RPL7A | GSM4909282 | Human | Breast | IDC | 1.04e-61 | -4.31e-01 | -0.0288 |
6130 | RPL7A | GSM4909285 | Human | Breast | IDC | 1.60e-09 | 1.32e-01 | 0.21 |
6130 | RPL7A | GSM4909286 | Human | Breast | IDC | 1.89e-02 | 1.05e-01 | 0.1081 |
6130 | RPL7A | GSM4909287 | Human | Breast | IDC | 2.97e-38 | -4.85e-01 | 0.2057 |
6130 | RPL7A | GSM4909290 | Human | Breast | IDC | 4.79e-14 | -2.87e-01 | 0.2096 |
6130 | RPL7A | GSM4909293 | Human | Breast | IDC | 1.20e-02 | -5.41e-02 | 0.1581 |
6130 | RPL7A | GSM4909295 | Human | Breast | IDC | 2.10e-11 | -3.25e-01 | 0.0898 |
6130 | RPL7A | GSM4909296 | Human | Breast | IDC | 3.49e-02 | 7.72e-02 | 0.1524 |
6130 | RPL7A | GSM4909297 | Human | Breast | IDC | 3.32e-15 | -3.45e-01 | 0.1517 |
6130 | RPL7A | GSM4909298 | Human | Breast | IDC | 1.14e-22 | -2.15e-01 | 0.1551 |
6130 | RPL7A | GSM4909299 | Human | Breast | IDC | 4.25e-05 | -8.32e-02 | 0.035 |
6130 | RPL7A | GSM4909301 | Human | Breast | IDC | 3.13e-33 | -3.30e-01 | 0.1577 |
6130 | RPL7A | GSM4909304 | Human | Breast | IDC | 4.83e-02 | -4.90e-02 | 0.1636 |
6130 | RPL7A | GSM4909306 | Human | Breast | IDC | 5.79e-04 | -8.96e-02 | 0.1564 |
6130 | RPL7A | GSM4909309 | Human | Breast | IDC | 6.15e-05 | -2.29e-01 | 0.0483 |
6130 | RPL7A | GSM4909311 | Human | Breast | IDC | 9.45e-06 | -1.01e-01 | 0.1534 |
6130 | RPL7A | GSM4909316 | Human | Breast | IDC | 1.38e-04 | -3.48e-01 | 0.21 |
6130 | RPL7A | GSM4909317 | Human | Breast | IDC | 1.08e-18 | -2.49e-01 | 0.1355 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004227318 | Prostate | BPH | ribosomal large subunit biogenesis | 33/3107 | 72/18723 | 6.29e-09 | 2.25e-07 | 33 |
GO:00063649 | Prostate | BPH | rRNA processing | 63/3107 | 225/18723 | 1.11e-05 | 1.51e-04 | 63 |
GO:00160729 | Prostate | BPH | rRNA metabolic process | 65/3107 | 236/18723 | 1.45e-05 | 1.87e-04 | 65 |
GO:00004705 | Prostate | BPH | maturation of LSU-rRNA | 13/3107 | 28/18723 | 2.22e-04 | 1.78e-03 | 13 |
GO:00344708 | Prostate | BPH | ncRNA processing | 84/3107 | 395/18723 | 8.44e-03 | 3.64e-02 | 84 |
GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
GO:002261319 | Prostate | Tumor | ribonucleoprotein complex biogenesis | 159/3246 | 463/18723 | 3.17e-19 | 1.52e-16 | 159 |
GO:004225419 | Prostate | Tumor | ribosome biogenesis | 96/3246 | 299/18723 | 2.76e-10 | 1.51e-08 | 96 |
GO:004227319 | Prostate | Tumor | ribosomal large subunit biogenesis | 34/3246 | 72/18723 | 4.52e-09 | 1.82e-07 | 34 |
GO:000636417 | Prostate | Tumor | rRNA processing | 69/3246 | 225/18723 | 5.98e-07 | 1.26e-05 | 69 |
GO:001607217 | Prostate | Tumor | rRNA metabolic process | 71/3246 | 236/18723 | 9.17e-07 | 1.79e-05 | 71 |
GO:000047014 | Prostate | Tumor | maturation of LSU-rRNA | 14/3246 | 28/18723 | 7.53e-05 | 7.86e-04 | 14 |
GO:003447013 | Prostate | Tumor | ncRNA processing | 94/3246 | 395/18723 | 6.02e-04 | 4.31e-03 | 94 |
GO:000218128 | Skin | AK | cytoplasmic translation | 101/1910 | 148/18723 | 5.98e-65 | 3.54e-61 | 101 |
GO:002261328 | Skin | AK | ribonucleoprotein complex biogenesis | 108/1910 | 463/18723 | 8.48e-17 | 6.27e-14 | 108 |
GO:004225427 | Skin | AK | ribosome biogenesis | 73/1910 | 299/18723 | 8.44e-13 | 2.08e-10 | 73 |
GO:000636420 | Skin | AK | rRNA processing | 53/1910 | 225/18723 | 4.35e-09 | 3.30e-07 | 53 |
GO:001607220 | Skin | AK | rRNA metabolic process | 54/1910 | 236/18723 | 9.23e-09 | 6.07e-07 | 54 |
GO:004227327 | Skin | AK | ribosomal large subunit biogenesis | 24/1910 | 72/18723 | 8.63e-08 | 4.02e-06 | 24 |
GO:003447016 | Skin | AK | ncRNA processing | 68/1910 | 395/18723 | 1.12e-05 | 2.33e-04 | 68 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL7A | deletion | Frame_Shift_Del | novel | c.188delT | p.Leu63CysfsTer12 | p.L63Cfs*12 | P62424 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
RPL7A | SNV | Missense_Mutation | c.507N>G | p.Phe169Leu | p.F169L | P62424 | protein_coding | deleterious(0.03) | benign(0.25) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
RPL7A | SNV | Missense_Mutation | c.30G>C | p.Lys10Asn | p.K10N | P62424 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
RPL7A | SNV | Missense_Mutation | novel | c.280N>G | p.Gln94Glu | p.Q94E | P62424 | protein_coding | tolerated(0.06) | benign(0.053) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RPL7A | SNV | Missense_Mutation | c.555N>T | p.Lys185Asn | p.K185N | P62424 | protein_coding | deleterious(0.01) | probably_damaging(0.934) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL7A | SNV | Missense_Mutation | novel | c.265C>A | p.Arg89Ser | p.R89S | P62424 | protein_coding | tolerated(0.06) | benign(0.113) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RPL7A | SNV | Missense_Mutation | novel | c.383N>C | p.Val128Ala | p.V128A | P62424 | protein_coding | tolerated(0.18) | benign(0.02) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL7A | SNV | Missense_Mutation | c.281A>G | p.Gln94Arg | p.Q94R | P62424 | protein_coding | deleterious(0.04) | benign(0.031) | TCGA-A5-A0GA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD | |
RPL7A | SNV | Missense_Mutation | rs14381 | c.478G>A | p.Asp160Asn | p.D160N | P62424 | protein_coding | tolerated(0.06) | benign(0.365) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL7A | SNV | Missense_Mutation | novel | c.481N>A | p.Val161Met | p.V161M | P62424 | protein_coding | tolerated(0.06) | possibly_damaging(0.868) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |